[
    [
        {
            "time": "",
            "original_text": "公告精选：东阿阿胶拟7.5亿至15亿回购股份；上海莱士将不再进行证券投资",
            "features": {
                "keywords": [
                    "东阿阿胶",
                    "回购股份",
                    "上海莱士",
                    "不再进行证券投资"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "公告精选：东阿阿胶拟7.5亿至15亿回购股份；上海莱士将不再进行证券投资",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "上海莱士回复交易所问询函：今后将不再进行证券投资 问询",
            "features": {
                "keywords": [
                    "上海莱士",
                    "不再进行证券投资",
                    "问询函"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "上海莱士回复交易所问询函：今后将不再进行证券投资 问询",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "步长制药销售费用占营收59%低于同行水平 商誉两年未减少转型大健康",
            "features": {
                "keywords": [
                    "步长制药",
                    "销售费用",
                    "商誉",
                    "转型大健康"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "大健康"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "步长制药销售费用占营收59%低于同行水平 商誉两年未减少转型大健康",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]